首页 > 最新文献

Journal of Clinical Medicine Research最新文献

英文 中文
Metabolomics in Acute Kidney Injury: The Experimental Perspective. 代谢组学在急性肾损伤中的应用:实验视角。
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4913
Daniel Patschan, Susann Patschan, Igor Matyukhin, Meike Hoffmeister, Martin Lauxmann, Oliver Ritter, Werner Dammermann

Acute kidney injury (AKI) affects increasing numbers of in-hospital patients in Central Europe and the USA, the prognosis remains poor. Although substantial progress has been achieved in the identification of molecular/cellular processes that induce and perpetuate AKI, more integrated pathophysiological perspectives are missing. Metabolomics enables the identification of low-molecular-weight (< 1.5 kD) substances from biological specimens such as certain types of fluid or tissue. The aim of the article was to review the literature on metabolic profiling in experimental AKI and to answer the question if metabolomics allows the integration of distinct pathophysiological events such as tubulopathy and microvasculopathy in ischemic and toxic AKI. The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1940 until 2022. The following terms were utilized: "acute kidney injury" OR "acute renal failure" OR "AKI" AND "metabolomics" OR "metabolic profiling" OR "omics" AND "ischemic" OR "toxic" OR "drug-induced" OR "sepsis" OR "LPS" OR "cisplatin" OR "cardiorenal" OR "CRS" AND "mouse" OR "mice" OR "murine" OR "rats" OR "rat". Additional search terms were "cardiac surgery", "cardiopulmonary bypass", "pig", "dog", and "swine". In total, 13 studies were identified. Five studies were related to ischemic, seven studies to toxic (lipopolysaccharide (LPS), cisplatin), and one study to heat shock-associated AKI. Only one study, related to cisplatin-induced AKI, was performed as a targeted analysis. The majority of the studies identified multiple metabolic deteriorations upon ischemia/the administration of LPS or cisplatin (e.g., amino acid, glucose, lipid metabolism). Particularly, abnormalities in the lipid homeostasis were shown under almost all experimental conditions. LPS-induced AKI most likely depends on the alterations in the tryptophan metabolism. Metabolomics studies provide a deeper understanding of pathophysiological links between distinct processes that are responsible for functional impairment/structural damage in ischemic or toxic or other types of AKI.

急性肾损伤(AKI)影响越来越多的住院患者在中欧和美国,预后仍然很差。尽管在确定诱发和延续AKI的分子/细胞过程方面取得了实质性进展,但缺乏更综合的病理生理观点。代谢组学能够从生物标本(如某些类型的液体或组织)中识别低分子量(< 1.5 kD)物质。本文的目的是回顾关于实验性AKI代谢谱的文献,并回答代谢组学是否允许在缺血性和中毒性AKI中整合不同的病理生理事件,如小管病变和微血管病变。检索了以下数据库:PubMed, Web of Science, Cochrane Library, Scopus。这一时期从1940年持续到2022年。使用了以下术语:“急性肾损伤”或“急性肾功能衰竭”或“AKI”和“代谢组学”或“代谢谱”或“组学”和“缺血”或“毒性”或“药物诱导”或“败血症”或“LPS”或“顺铂”或“心肾”或“CRS”和“小鼠”或“小鼠”或“大鼠”或“大鼠”。其他搜索词包括“心脏手术”、“体外循环”、“猪”、“狗”和“猪”。总共确定了13项研究。五项研究与缺血性有关,七项研究与毒性(脂多糖(LPS),顺铂)有关,一项研究与热休克相关的AKI有关。只有一项与顺铂诱导的AKI相关的研究被作为靶向分析进行。大多数研究发现缺血/给药LPS或顺铂后多种代谢恶化(如氨基酸、葡萄糖、脂质代谢)。特别是,在几乎所有的实验条件下,脂质稳态都表现出异常。lps诱导的AKI很可能与色氨酸代谢的改变有关。代谢组学研究为缺血性、中毒性或其他类型AKI中导致功能损伤/结构损伤的不同过程之间的病理生理联系提供了更深入的了解。
{"title":"Metabolomics in Acute Kidney Injury: The Experimental Perspective.","authors":"Daniel Patschan,&nbsp;Susann Patschan,&nbsp;Igor Matyukhin,&nbsp;Meike Hoffmeister,&nbsp;Martin Lauxmann,&nbsp;Oliver Ritter,&nbsp;Werner Dammermann","doi":"10.14740/jocmr4913","DOIUrl":"https://doi.org/10.14740/jocmr4913","url":null,"abstract":"<p><p>Acute kidney injury (AKI) affects increasing numbers of in-hospital patients in Central Europe and the USA, the prognosis remains poor. Although substantial progress has been achieved in the identification of molecular/cellular processes that induce and perpetuate AKI, more integrated pathophysiological perspectives are missing. Metabolomics enables the identification of low-molecular-weight (< 1.5 kD) substances from biological specimens such as certain types of fluid or tissue. The aim of the article was to review the literature on metabolic profiling in experimental AKI and to answer the question if metabolomics allows the integration of distinct pathophysiological events such as tubulopathy and microvasculopathy in ischemic and toxic AKI. The following databases were searched for references: PubMed, Web of Science, Cochrane Library, Scopus. The period lasted from 1940 until 2022. The following terms were utilized: \"acute kidney injury\" OR \"acute renal failure\" OR \"AKI\" AND \"metabolomics\" OR \"metabolic profiling\" OR \"omics\" AND \"ischemic\" OR \"toxic\" OR \"drug-induced\" OR \"sepsis\" OR \"LPS\" OR \"cisplatin\" OR \"cardiorenal\" OR \"CRS\" AND \"mouse\" OR \"mice\" OR \"murine\" OR \"rats\" OR \"rat\". Additional search terms were \"cardiac surgery\", \"cardiopulmonary bypass\", \"pig\", \"dog\", and \"swine\". In total, 13 studies were identified. Five studies were related to ischemic, seven studies to toxic (lipopolysaccharide (LPS), cisplatin), and one study to heat shock-associated AKI. Only one study, related to cisplatin-induced AKI, was performed as a targeted analysis. The majority of the studies identified multiple metabolic deteriorations upon ischemia/the administration of LPS or cisplatin (e.g., amino acid, glucose, lipid metabolism). Particularly, abnormalities in the lipid homeostasis were shown under almost all experimental conditions. LPS-induced AKI most likely depends on the alterations in the tryptophan metabolism. Metabolomics studies provide a deeper understanding of pathophysiological links between distinct processes that are responsible for functional impairment/structural damage in ischemic or toxic or other types of AKI.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"283-291"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/cd/jocmr-15-283.PMC10332883.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Resolution of Sinus Tachycardia Secondary to Hyperthyroidism With Ivabradine. 用伊伐布雷定缓解甲状腺功能亢进继发的窦性心动过速
Pub Date : 2023-06-01 Epub Date: 2023-06-29 DOI: 10.14740/jocmr4940
Yelizaveta Medina, Asif Khan, Jonathon Spagnola, James Lafferty

Currently, ivabradine is not approved for the treatment of sinus tachycardia secondary to hyperthyroidism. We aimed to increase the recognition of ivabradine as an effective alternative to, or combination with, beta-blockers in controlling sinus tachycardia secondary to hyperthyroidism. Elevated thyroid hormone levels enhance cardiac performance through a positive chronotropic effect, resulting in an increased heart rate (HR), an effect brought on by increasing the If funny current at sinoatrial node (SAN). Ivabradine is a novel, dose-dependent selective inhibitor of If channels. By decreasing SAN pacemaker activity, ivabradine allows for selective reduction of HR with a resultant increase in ventricular filling time. This mechanism sets ivabradine apart from the typical rate-reducing medications, namely beta-blockers and calcium channel blockers, which simultaneously decrease HR and myocardial contractility. We describe a case of hyperthyroidism-induced sinus tachycardia, resistant to maximal doses of beta-blocker, which was successfully managed by ivabradine. After excluding other causes of tachycardia, such as anemia, hypovolemic states, structural heart disease, drug abuse, and infection, ivabradine was given off-label for symptomatic relief of hyperthyroidism-induced sinus tachycardia. Within 24 h, HR steadily decreased to the low 80s. Our patient had a unique presentation in which he presented with hyperthyroidism-induced sinus tachycardia with no relief after administration of maximal dose of beta-blocker. Ivabradine was then given, with resolution of sinus tachycardia within 24 h.

目前,伊伐布雷定尚未被批准用于治疗甲亢继发的窦性心动过速。我们的目标是让更多人认识到伊伐布雷定可有效替代或联合β-受体阻滞剂控制甲亢继发的窦性心动过速。甲状腺激素水平升高可通过正性时序效应提高心脏性能,从而导致心率(HR)增加,这种效应是通过增加窦房结(SAN)的滑稽电流产生的。伊伐布雷定是一种新型、剂量依赖性的 If 通道选择性抑制剂。通过降低 SAN 起搏器的活性,伊伐布雷定可选择性地降低心率,从而延长心室充盈时间。这种机制使伊伐布雷定有别于典型的降心率药物,即同时降低心率和心肌收缩力的β受体阻滞剂和钙通道阻滞剂。我们描述了一例甲状腺功能亢进引起的窦性心动过速病例,患者对最大剂量的β-受体阻滞剂产生耐药性,伊伐布雷定成功地控制了患者的病情。在排除其他心动过速原因(如贫血、低血容量状态、结构性心脏病、药物滥用和感染)后,患者在标签外使用伊伐布雷定对甲亢诱发的窦性心动过速进行对症缓解。24 小时内,心率稳步下降至 80 多分。我们的患者有一个独特的病例,他出现甲状腺功能亢进诱发的窦性心动过速,服用最大剂量的β-受体阻滞剂后症状仍无缓解。随后他服用了伊伐布雷定,窦性心动过速在 24 小时内得到缓解。
{"title":"Resolution of Sinus Tachycardia Secondary to Hyperthyroidism With Ivabradine.","authors":"Yelizaveta Medina, Asif Khan, Jonathon Spagnola, James Lafferty","doi":"10.14740/jocmr4940","DOIUrl":"10.14740/jocmr4940","url":null,"abstract":"<p><p>Currently, ivabradine is not approved for the treatment of sinus tachycardia secondary to hyperthyroidism. We aimed to increase the recognition of ivabradine as an effective alternative to, or combination with, beta-blockers in controlling sinus tachycardia secondary to hyperthyroidism. Elevated thyroid hormone levels enhance cardiac performance through a positive chronotropic effect, resulting in an increased heart rate (HR), an effect brought on by increasing the <i>I<sub>f</sub></i> funny current at sinoatrial node (SAN). Ivabradine is a novel, dose-dependent selective inhibitor of <i>I<sub>f</sub></i> channels. By decreasing SAN pacemaker activity, ivabradine allows for selective reduction of HR with a resultant increase in ventricular filling time. This mechanism sets ivabradine apart from the typical rate-reducing medications, namely beta-blockers and calcium channel blockers, which simultaneously decrease HR and myocardial contractility. We describe a case of hyperthyroidism-induced sinus tachycardia, resistant to maximal doses of beta-blocker, which was successfully managed by ivabradine. After excluding other causes of tachycardia, such as anemia, hypovolemic states, structural heart disease, drug abuse, and infection, ivabradine was given off-label for symptomatic relief of hyperthyroidism-induced sinus tachycardia. Within 24 h, HR steadily decreased to the low 80s. Our patient had a unique presentation in which he presented with hyperthyroidism-induced sinus tachycardia with no relief after administration of maximal dose of beta-blocker. Ivabradine was then given, with resolution of sinus tachycardia within 24 h.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"336-339"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/f0/jocmr-15-336.PMC10332879.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoperative Risk Factors in Patients With Pancreatic Cancer. 胰腺癌患者术前危险因素分析。
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4906
Naomi Kusama, Yuta Mitobe, Natsuko Hyodo, Tetsuya Miyashita, Yasuko Baba, Takuya Hashimoto, Yoshimi Inagaki

Background: Pancreatic cancer is gastrointestinal cancer with a poor prognosis. Although surgical techniques and chemotherapy have improved treatment outcomes, the 5-year survival rate for pancreatic cancer is less than 10%. In addition, resection of pancreatic cancer is highly invasive and is associated with high rates of postoperative complications and hospital mortality. The Japanese Pancreatic Association states that preoperative body composition assessment may predict postoperative complications. However, although impaired physical function is also a risk factor, few studies have examined it in combination with body composition. We examined preoperative nutritional status and physical function as risk factors for postoperative complications in pancreatic cancer patients.

Methods: Fifty-nine patients with pancreatic cancer who underwent surgical treatment and were discharged alive from January 1, 2018, to March 31, 2021, at the Japanese Red Cross Medical Center. This retrospective study was conducted using electronic medical records and a database of departments. Body composition and physical function were evaluated before and after surgery, and the risk factors between patients with and without complications were compared.

Results: Fifty-nine patients were analyzed: 14 and 45 patients in the uncomplicated and complicated groups, respectively. The major complications were pancreatic fistulas (33%) and infections (22%). There were significant differences in: age, 74.0 (44 - 88) (P = 0.02); walking speed, 0.93 m/s (0.3 - 2.2) (P = 0.01); and fat mass, 16.50 kg (4.7 - 46.2) (P = 0.02), in the patients with complications. On Multivariable logistic regression analysis, age (odds ratio: 2.28; confidence interval (CI): 1.3400 - 569.00; P = 0.03), preoperative fat mass (odds ratio: 2.28; CI: 1.4900 - 168.00; P = 0.02), and walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) were identified as risk factors. Walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) was the risk factor that was extracted.

Conclusions: Older age, more preoperative fat mass, and decreased walking speed were possible risk factors for postoperative complications.

背景:胰腺癌是一种预后较差的胃肠道肿瘤。虽然手术技术和化疗改善了治疗效果,但胰腺癌的5年生存率不到10%。此外,胰腺癌切除术是高度侵入性的,与术后并发症和住院死亡率高相关。日本胰腺协会指出,术前身体成分评估可以预测术后并发症。然而,尽管身体机能受损也是一个风险因素,但很少有研究将其与身体成分结合起来进行研究。我们研究了胰腺癌患者术前营养状况和身体功能作为术后并发症的危险因素。方法:2018年1月1日至2021年3月31日在日本红十字会医疗中心接受手术治疗并存活出院的59例胰腺癌患者。本研究采用电子病历和科室数据库进行回顾性研究。评估手术前后的身体成分和身体功能,比较有无并发症患者的危险因素。结果:共分析59例患者,无并发症组14例,并发症组45例。主要并发症为胰瘘(33%)和感染(22%)。年龄为74.0(44 ~ 88岁),差异有统计学意义(P = 0.02);步行速度:0.93 m/s (0.3 ~ 2.2) (P = 0.01);并发症患者脂肪质量16.50 kg (4.7 ~ 46.2) (P = 0.02)。多变量logistic回归分析,年龄(优势比:2.28;置信区间(CI): 1.3400 - 569.00;P = 0.03),术前脂肪量(优势比:2.28;Ci: 1.4900 - 168.00;P = 0.02)、步行速度(优势比:0.119;Ci: 0.0134 - 1.07;P = 0.05)为危险因素。步行速度(优势比:0.119;Ci: 0.0134 - 1.07;P = 0.05)为提取的危险因素。结论:年龄较大、术前脂肪量较大、行走速度减慢是术后并发症的可能危险因素。
{"title":"Preoperative Risk Factors in Patients With Pancreatic Cancer.","authors":"Naomi Kusama,&nbsp;Yuta Mitobe,&nbsp;Natsuko Hyodo,&nbsp;Tetsuya Miyashita,&nbsp;Yasuko Baba,&nbsp;Takuya Hashimoto,&nbsp;Yoshimi Inagaki","doi":"10.14740/jocmr4906","DOIUrl":"https://doi.org/10.14740/jocmr4906","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is gastrointestinal cancer with a poor prognosis. Although surgical techniques and chemotherapy have improved treatment outcomes, the 5-year survival rate for pancreatic cancer is less than 10%. In addition, resection of pancreatic cancer is highly invasive and is associated with high rates of postoperative complications and hospital mortality. The Japanese Pancreatic Association states that preoperative body composition assessment may predict postoperative complications. However, although impaired physical function is also a risk factor, few studies have examined it in combination with body composition. We examined preoperative nutritional status and physical function as risk factors for postoperative complications in pancreatic cancer patients.</p><p><strong>Methods: </strong>Fifty-nine patients with pancreatic cancer who underwent surgical treatment and were discharged alive from January 1, 2018, to March 31, 2021, at the Japanese Red Cross Medical Center. This retrospective study was conducted using electronic medical records and a database of departments. Body composition and physical function were evaluated before and after surgery, and the risk factors between patients with and without complications were compared.</p><p><strong>Results: </strong>Fifty-nine patients were analyzed: 14 and 45 patients in the uncomplicated and complicated groups, respectively. The major complications were pancreatic fistulas (33%) and infections (22%). There were significant differences in: age, 74.0 (44 - 88) (P = 0.02); walking speed, 0.93 m/s (0.3 - 2.2) (P = 0.01); and fat mass, 16.50 kg (4.7 - 46.2) (P = 0.02), in the patients with complications. On Multivariable logistic regression analysis, age (odds ratio: 2.28; confidence interval (CI): 1.3400 - 569.00; P = 0.03), preoperative fat mass (odds ratio: 2.28; CI: 1.4900 - 168.00; P = 0.02), and walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) were identified as risk factors. Walking speed (odds ratio: 0.119; CI: 0.0134 - 1.07; P = 0.05) was the risk factor that was extracted.</p><p><strong>Conclusions: </strong>Older age, more preoperative fat mass, and decreased walking speed were possible risk factors for postoperative complications.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"300-309"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/42/jocmr-15-300.PMC10332881.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low Accuracy of Antenatal Screening for Group B Streptococcus From Perianal Area. 产前肛周B群链球菌筛查准确率低。
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4927
Shunji Suzuki
Group B streptococcus (GBS) is recognized as the most frequent cause of severe early-onset infection in newborn infants. GBS has been observed to be present in the bowel flora of 17.4% of adults (colonization) including pregnant women, and those who are colonized are called “carriers” [1]. To date, more than half of early-onset GBS disease has been reported to occur in neonates born to women with negative GBS screening tests [2, 3]. For example, the recent article in Japan by Miyata et al [2] has also concerned that early-onset GBS disease can develop in infants who are born to mothers with negative GBS screening results. The timing of GBS screening at 35 37 weeks recommended by the Centers for Disease Control and Prevention (CDC) [4] and the American College of Obstetricians and Gynecologists (ACOG) [5] was established based on an earlier study by Yancey et al [6], which indicated that the accuracy of late antenatal anogenital cultures in predicting GBS colonization at delivery is high in cultures collected at 1 5 weeks before delivery. In their observation, the sensitivity, specificity, positive predictive value, and negative predictive value of GBS cultures at 1 5 weeks before delivery for identifying colonization status at delivery were 87%, 96%, 87%, and 96%, respectively. While they were only 43%, 85%, 50%, and 81%, respectively among patients cultured 6 or more weeks before delivery. In their observation [6], a swab for culture specimen was inserted through the anal sphincter; however, the vaginal-perianal collection method has been indicated to be less painful and comfortable [7]. In some recent examinations [7-9], the detection rates of GBS culture from the (vaginal-) perianal area have been observed to be similar to that of anorectal specimens; however, the accuracy of antenatal screening for GBS with cultures from the perianal area has not been well examined. The protocol for this prospective study was approved by the Ethics Committee of Japanese Red Cross Katsushika Maternity Hospital (K2007-15). Informed consent concerning analysis was obtained from all subjects. We performed maternal GBS culture from perianal area used non-selective enrichment medium in 93 Japanese pregnant women scheduled vaginal delivery with GBS-positive at 35 weeks’ gestation every week until delivery. Of these, 84 (90%) delivered at ≤ 40 weeks’ gestation (within 5 weeks). The clinical characteristics of the 84 women are shown in Table 1. All women received the administration of ampicillin intravenous (IV) during labor or after premature membrane rupture. Fortunately, there were no cases of neonatal infection as shown in Table 1. At 36 weeks’ gestation, 62 of these were defined as GBSpositive (positive predictive value: 74%), while 22 (26%) were negative. At 37 weeks’ gestation, the different results from those of the previous week (36 weeks’ gestation) were defined in 29 (15 + 14: 35%) women as shown in Figure 1. At the last perinatal visits, GBS-positive was d
{"title":"Low Accuracy of Antenatal Screening for Group B Streptococcus From Perianal Area.","authors":"Shunji Suzuki","doi":"10.14740/jocmr4927","DOIUrl":"https://doi.org/10.14740/jocmr4927","url":null,"abstract":"Group B streptococcus (GBS) is recognized as the most frequent cause of severe early-onset infection in newborn infants. GBS has been observed to be present in the bowel flora of 17.4% of adults (colonization) including pregnant women, and those who are colonized are called “carriers” [1]. To date, more than half of early-onset GBS disease has been reported to occur in neonates born to women with negative GBS screening tests [2, 3]. For example, the recent article in Japan by Miyata et al [2] has also concerned that early-onset GBS disease can develop in infants who are born to mothers with negative GBS screening results. The timing of GBS screening at 35 37 weeks recommended by the Centers for Disease Control and Prevention (CDC) [4] and the American College of Obstetricians and Gynecologists (ACOG) [5] was established based on an earlier study by Yancey et al [6], which indicated that the accuracy of late antenatal anogenital cultures in predicting GBS colonization at delivery is high in cultures collected at 1 5 weeks before delivery. In their observation, the sensitivity, specificity, positive predictive value, and negative predictive value of GBS cultures at 1 5 weeks before delivery for identifying colonization status at delivery were 87%, 96%, 87%, and 96%, respectively. While they were only 43%, 85%, 50%, and 81%, respectively among patients cultured 6 or more weeks before delivery. In their observation [6], a swab for culture specimen was inserted through the anal sphincter; however, the vaginal-perianal collection method has been indicated to be less painful and comfortable [7]. In some recent examinations [7-9], the detection rates of GBS culture from the (vaginal-) perianal area have been observed to be similar to that of anorectal specimens; however, the accuracy of antenatal screening for GBS with cultures from the perianal area has not been well examined. The protocol for this prospective study was approved by the Ethics Committee of Japanese Red Cross Katsushika Maternity Hospital (K2007-15). Informed consent concerning analysis was obtained from all subjects. We performed maternal GBS culture from perianal area used non-selective enrichment medium in 93 Japanese pregnant women scheduled vaginal delivery with GBS-positive at 35 weeks’ gestation every week until delivery. Of these, 84 (90%) delivered at ≤ 40 weeks’ gestation (within 5 weeks). The clinical characteristics of the 84 women are shown in Table 1. All women received the administration of ampicillin intravenous (IV) during labor or after premature membrane rupture. Fortunately, there were no cases of neonatal infection as shown in Table 1. At 36 weeks’ gestation, 62 of these were defined as GBSpositive (positive predictive value: 74%), while 22 (26%) were negative. At 37 weeks’ gestation, the different results from those of the previous week (36 weeks’ gestation) were defined in 29 (15 + 14: 35%) women as shown in Figure 1. At the last perinatal visits, GBS-positive was d","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"340-342"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/05/jocmr-15-340.PMC10332875.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of COVID-19 on Sepsis-Related Mortality in the United States. COVID-19对美国败血症相关死亡率的影响
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4937
Lavi Oud, John Garza

Background: Coronavirus disease 2019 (COVID-19)-related organ dysfunction is increasingly considered as sepsis of viral origin. In recent clinical and autopsy studies, sepsis has been present in the majority of decedents with COVID-19. Given the high mortality toll of COVID-19, sepsis epidemiology would be expected to be substantially transformed. However, the impact of COVID-19 on sepsis-related mortality at the national level has not been quantified. We aimed to estimate the contribution of COVID-19 to sepsis-related mortality in the USA during the first year of the pandemic.

Methods: We used the Centers for Disease Control Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) Multiple Cause of Death dataset to identify decedents with sepsis during 2015 - 2019, and those with a diagnosis of sepsis, COVID-19, or both in 2020. Negative binomial regression was used on the 2015 - 2019 data to forecast the number of sepsis-related deaths in 2020. We then compared the observed vs. predicted number of sepsis-related deaths in 2020. In addition, we examined the frequency of a diagnosis of COVID-19 among decedents with sepsis and the proportion of a diagnosis of sepsis among decedents with COVID-19. The latter analysis was repeated within each of the Department of Health and Human Services (HHS) regions.

Results: In 2020, there were 242,630 sepsis-related deaths, 384,536 COVID-19-related deaths, and 35,807 deaths with both in the USA. The predicted number of sepsis-related deaths for 2020 was 206,549 (95% confidence interval (CI): 201,550 - 211,671). COVID-19 was reported in 14.7% of decedents with sepsis, while a diagnosis of sepsis was reported in 9.3% of all COVID-19-related deaths, ranging from 6.7% to 12.8% across HHS regions.

Conclusions: A diagnosis of COVID-19 was reported in less than one in six of decedents with sepsis in 2020, with corresponding less than one in 10 diagnoses of sepsis among decedents with COVID-19. These findings suggest that death certificate-based data may have substantially underestimated the toll of sepsis-related deaths in the USA during the first year of the pandemic.

背景:冠状病毒病2019 (COVID-19)相关器官功能障碍越来越被认为是病毒源性败血症。在最近的临床和尸检研究中,大多数COVID-19死者都存在败血症。鉴于COVID-19的高死亡率,预计败血症流行病学将发生重大转变。然而,在国家层面上,COVID-19对败血症相关死亡率的影响尚未量化。我们的目的是估计COVID-19在大流行的第一年对美国败血症相关死亡率的贡献。方法:我们使用疾病控制中心广泛的流行病学研究在线数据(CDC WONDER)多死因数据集来识别2015 - 2019年期间败血症的死者,以及2020年诊断为败血症、COVID-19或两者兼有的死者。对2015 - 2019年的数据采用负二项回归预测2020年败血症相关死亡人数。然后,我们比较了2020年观察到的与预测的败血症相关死亡人数。此外,我们检查了败血症患者中诊断为COVID-19的频率以及COVID-19患者中诊断为败血症的比例。后一项分析在卫生与公众服务部(HHS)的每个区域内重复进行。结果:2020年,美国与败血症相关的死亡人数为242630人,与covid -19相关的死亡人数为384536人,两者死亡人数为35807人。预计2020年败血症相关死亡人数为206,549人(95%置信区间(CI): 201,550 - 211,671)。在败血症患者中,14.7%报告了COVID-19,而在所有与COVID-19相关的死亡中,9.3%报告了败血症诊断,在卫生与公众服务部各地区从6.7%到12.8%不等。结论:2020年,在败血症患者中,只有不到六分之一的人诊断出了COVID-19,相应地,在COVID-19患者中,只有不到十分之一的人诊断出了败血症。这些发现表明,基于死亡证明的数据可能大大低估了大流行第一年美国败血症相关死亡人数。
{"title":"The Impact of COVID-19 on Sepsis-Related Mortality in the United States.","authors":"Lavi Oud,&nbsp;John Garza","doi":"10.14740/jocmr4937","DOIUrl":"https://doi.org/10.14740/jocmr4937","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19)-related organ dysfunction is increasingly considered as sepsis of viral origin. In recent clinical and autopsy studies, sepsis has been present in the majority of decedents with COVID-19. Given the high mortality toll of COVID-19, sepsis epidemiology would be expected to be substantially transformed. However, the impact of COVID-19 on sepsis-related mortality at the national level has not been quantified. We aimed to estimate the contribution of COVID-19 to sepsis-related mortality in the USA during the first year of the pandemic.</p><p><strong>Methods: </strong>We used the Centers for Disease Control Wide-Ranging Online Data for Epidemiological Research (CDC WONDER) Multiple Cause of Death dataset to identify decedents with sepsis during 2015 - 2019, and those with a diagnosis of sepsis, COVID-19, or both in 2020. Negative binomial regression was used on the 2015 - 2019 data to forecast the number of sepsis-related deaths in 2020. We then compared the observed vs. predicted number of sepsis-related deaths in 2020. In addition, we examined the frequency of a diagnosis of COVID-19 among decedents with sepsis and the proportion of a diagnosis of sepsis among decedents with COVID-19. The latter analysis was repeated within each of the Department of Health and Human Services (HHS) regions.</p><p><strong>Results: </strong>In 2020, there were 242,630 sepsis-related deaths, 384,536 COVID-19-related deaths, and 35,807 deaths with both in the USA. The predicted number of sepsis-related deaths for 2020 was 206,549 (95% confidence interval (CI): 201,550 - 211,671). COVID-19 was reported in 14.7% of decedents with sepsis, while a diagnosis of sepsis was reported in 9.3% of all COVID-19-related deaths, ranging from 6.7% to 12.8% across HHS regions.</p><p><strong>Conclusions: </strong>A diagnosis of COVID-19 was reported in less than one in six of decedents with sepsis in 2020, with corresponding less than one in 10 diagnoses of sepsis among decedents with COVID-19. These findings suggest that death certificate-based data may have substantially underestimated the toll of sepsis-related deaths in the USA during the first year of the pandemic.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"328-331"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/b7/jocmr-15-328.PMC10332882.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9811861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Colon Cancer Risk Following Intestinal Clostridioides difficile Infection: A Longitudinal Cohort Study. 肠难辨梭菌感染后结肠癌风险:一项纵向队列研究。
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4919
David A Geier, Mark R Geier

Background: The gut microbiome may play an important role in the etiology and progression of colon cancer. The present hypothesis-testing study compared the colon cancer incidence rate among adults diagnosed with intestinal Clostridioides (formerly Clostridium) difficile (Cdiff) (the Cdiff cohort) to adults not diagnosed with intestinal Cdiff infection (the non-Cdiff cohort).

Methods: De-identified eligibility and claim healthcare records within the Independent Healthcare Research Database (IHRD) from a longitudinal cohort of adults (the overall cohort) enrolled in the Florida Medicaid system between 1990 through 2012 were examined. Adults with ≥ 8 outpatient office visits over 8 years of continuous eligibility were examined. There were 964 adults in the Cdiff cohort and 292,136 adults in the non-Cdiff cohort. Frequency and Cox proportional hazards models were utilized.

Results: Colon cancer incidence rate in the non-Cdiff cohort remained relatively uniform over the entire study period, whereas a marked increase was observed in the Cdiff cohort within the first 4 years of a Cdiff diagnosis. Colon cancer incidence was significantly increased (about 2.7-fold) in the Cdiff cohort (3.11 per 1,000 person-years) compared to the non-Cdiff cohort (1.16 per 1,000 person-years). Adjustments for gender, age, residency, birthdate, colonoscopy screening, family history of cancer, and personal history of tobacco abuse, alcohol abuse/dependence, drug abuse/dependence, and overweight/obesity, as well as consideration of diagnostic status for ulcerative and infection colitis, immunodeficiency, and personal history of cancer did not significantly change the observed results.

Conclusions: This is the first epidemiological study associating Cdiff with an increased risk for colon cancer. Future studies should further evaluate this relationship.

背景:肠道微生物群可能在结肠癌的病因和进展中发挥重要作用。目前的假设检验研究比较了诊断为肠道艰难梭菌(Cdiff)的成年人(Cdiff队列)和未诊断为肠道艰难梭菌感染的成年人(非Cdiff队列)的结肠癌发病率。方法:在独立医疗研究数据库(IHRD)中,对1990年至2012年期间在佛罗里达州医疗补助系统登记的成年人(总体队列)进行纵向队列检查,以确定资格和索赔医疗记录。研究对象为连续8年以上门诊次数≥8次的成人。在Cdiff队列中有964名成年人,在非Cdiff队列中有292136名成年人。采用频率和Cox比例风险模型。结果:在整个研究期间,非Cdiff队列中的结肠癌发病率保持相对一致,而在Cdiff诊断的前4年内,Cdiff队列中观察到显着增加。与非Cdiff组(1.16 / 1000人年)相比,Cdiff组的结肠癌发病率显著增加(约2.7倍)(3.11 / 1000人年)。调整性别、年龄、居住地、出生、结肠镜筛查、癌症家族史、个人吸烟史、酒精滥用/依赖史、药物滥用/依赖史、超重/肥胖史,以及考虑溃疡性和感染性结肠炎、免疫缺陷和个人癌症史的诊断状态,均未显著改变观察结果。结论:这是第一个将Cdiff与结肠癌风险增加联系起来的流行病学研究。未来的研究应进一步评估这种关系。
{"title":"Colon Cancer Risk Following Intestinal <i>Clostridioides difficile</i> Infection: A Longitudinal Cohort Study.","authors":"David A Geier,&nbsp;Mark R Geier","doi":"10.14740/jocmr4919","DOIUrl":"https://doi.org/10.14740/jocmr4919","url":null,"abstract":"<p><strong>Background: </strong>The gut microbiome may play an important role in the etiology and progression of colon cancer. The present hypothesis-testing study compared the colon cancer incidence rate among adults diagnosed with intestinal <i>Clostridioides</i> (formerly <i>Clostridium) difficile</i> (Cdiff) (the Cdiff cohort) to adults not diagnosed with intestinal Cdiff infection (the non-Cdiff cohort).</p><p><strong>Methods: </strong>De-identified eligibility and claim healthcare records within the Independent Healthcare Research Database (IHRD) from a longitudinal cohort of adults (the overall cohort) enrolled in the Florida Medicaid system between 1990 through 2012 were examined. Adults with ≥ 8 outpatient office visits over 8 years of continuous eligibility were examined. There were 964 adults in the Cdiff cohort and 292,136 adults in the non-Cdiff cohort. Frequency and Cox proportional hazards models were utilized.</p><p><strong>Results: </strong>Colon cancer incidence rate in the non-Cdiff cohort remained relatively uniform over the entire study period, whereas a marked increase was observed in the Cdiff cohort within the first 4 years of a Cdiff diagnosis. Colon cancer incidence was significantly increased (about 2.7-fold) in the Cdiff cohort (3.11 per 1,000 person-years) compared to the non-Cdiff cohort (1.16 per 1,000 person-years). Adjustments for gender, age, residency, birthdate, colonoscopy screening, family history of cancer, and personal history of tobacco abuse, alcohol abuse/dependence, drug abuse/dependence, and overweight/obesity, as well as consideration of diagnostic status for ulcerative and infection colitis, immunodeficiency, and personal history of cancer did not significantly change the observed results.</p><p><strong>Conclusions: </strong>This is the first epidemiological study associating Cdiff with an increased risk for colon cancer. Future studies should further evaluate this relationship.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"310-320"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/7b/jocmr-15-310.PMC10332880.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of Telestroke Inter-Hospital Transfers Among Intervention and Non-Intervention Patients. 干预与非干预患者中风住院转院的结果。
Pub Date : 2023-06-01 DOI: 10.14740/jocmr4945
Adalia H Jun-O'Connell, Shravan Sivakumar, Nils Henninger, Brian Silver, Meghna Trivedi, Mehdi Ghasemi, Rakhee R Lalla, Kimiyoshi J Kobayashi

Background: Telestroke is an established telemedicine method of delivering emergency stroke care. However, not all neurological patients utilizing telestroke service require emergency interventions or transfer to a comprehensive stroke center. To develop an understanding of the appropriateness of inter-hospital neurological transfers utilizing the telemedicine, our study aimed to assess the differences in outcomes of inter-hospital transfers utilizing the service in relation to the need for neurological interventions.

Methods: The pragmatic, retrospective analysis included 181 consecutive patients, who were emergently transferred from telestroke-affiliated regional medical centers between October 3, 2021, and May 3, 2022. In this exploratory study investigating the outcomes of telestroke-referred patients, patients receiving interventions were compared to those that did not following transfer to our tertiary center. Neurological interventions included mechanical thrombectomy (MT) and/or tissue plasminogen activator (tPA), craniectomy, electroencephalography (EEG), or external ventricular drain (EVD). Transfer mortality rate, discharge functional status defined by modified Rankin scale (mRS), neurological status defined by National Institutes of Health Stroke Scale (NIHSS), 30-day unpreventable readmission rate, 90-day clinical major adverse cardiovascular events (MACE), and 90-day mRS, and NIHSS were studied. We used χ2 or Fisher exact tests to evaluate the association between the intervention and categorical or dichotomous variables. Continuous or ordinal measures were compared using Wilcoxon rank-sum tests. All tests of statistical significance were considered to be significant at P < 0.05.

Results: Among the 181 transferred patients, 114 (63%) received neuro-intervention and 67 (37%) did not. The death rate during the index admission was not statistically significant between the intervention and non-intervention groups (P = 0.196). The discharge NIHSS and mRS were worse in the intervention compared to the non-intervention (P < 0.05 each, respectively). The 90-day mortality and cardiovascular event rates were similar between intervention and non-intervention groups (P > 0.05 each, respectively). The 30-day readmission rates were also similar between the two groups (14% intervention vs. 13.4% non-intervention, P = 0.910). The 90-day mRS were not significantly different between intervention and non-intervention groups (median 3 (IQR: 1 - 6) vs. 2 (IQR: 0 - 6), P = 0.109). However, 90-day NIHSS was worse in the intervention compared to non-intervention group (median 2 (IQR: 0 - 11) vs. 0 (IQR: 0 - 3), P = 0.004).

Conclusions: Telestroke is a valuable resource that expedites emergent neurological care via referral to a stroke center. However, not all transferred patients benefit from the transfer process. Future multicenter studies are warranted to s

背景:远程脑卒中是一种成熟的远程医疗方法,提供紧急脑卒中护理。然而,并非所有使用远程中风服务的神经系统患者都需要紧急干预或转移到综合中风中心。为了了解利用远程医疗进行医院间神经转诊的适当性,我们的研究旨在评估利用该服务的医院间转诊结果与神经干预需求的差异。方法:采用实用的回顾性分析方法,纳入了2021年10月3日至2022年5月3日期间从远程卒中附属地区医疗中心紧急转院的181例连续患者。在这项探索性研究中,研究了卒中转诊患者的预后,将接受干预的患者与未接受干预的患者进行了比较。神经系统干预包括机械取栓(MT)和/或组织型纤溶酶原激活剂(tPA)、颅骨切除术、脑电图(EEG)或外脑室引流(EVD)。研究转院死亡率、改良Rankin量表(mRS)定义的出院功能状态、美国国立卫生研究院卒中量表(NIHSS)定义的神经系统状态、30天不可预防再入院率、90天临床主要心血管不良事件(MACE)、90天mRS和NIHSS。我们使用χ2或Fisher精确检验来评估干预措施与分类变量或二分类变量之间的相关性。使用Wilcoxon秩和检验比较连续或顺序测量。所有检验均以P < 0.05为显著性。结果:在181例转院患者中,114例(63%)接受了神经干预,67例(37%)未接受神经干预。干预组与非干预组入院时的死亡率比较,差异无统计学意义(P = 0.196)。干预组的出院NIHSS和mRS均低于未干预组(P < 0.05)。干预组与非干预组90天死亡率、心血管事件发生率比较,差异均无统计学意义(P > 0.05)。两组患者的30天再入院率也相似(干预组为14%,非干预组为13.4%,P = 0.910)。90天mRS在干预组和非干预组之间无显著差异(中位数3 (IQR: 1 - 6) vs. 2 (IQR: 0- 6), P = 0.109)。然而,干预组90天NIHSS较非干预组差(中位数2 (IQR: 0- 11)比0 (IQR: 0- 3), P = 0.004)。结论:卒中是一个宝贵的资源,通过转诊到卒中中心加快紧急神经护理。然而,并不是所有的转院患者都能从转院过程中获益。未来的多中心研究有必要研究远程中风网络的效果或适宜性,并更好地了解患者特征、资源分配和转移机构,以改善远程中风护理。
{"title":"Outcomes of Telestroke Inter-Hospital Transfers Among Intervention and Non-Intervention Patients.","authors":"Adalia H Jun-O'Connell,&nbsp;Shravan Sivakumar,&nbsp;Nils Henninger,&nbsp;Brian Silver,&nbsp;Meghna Trivedi,&nbsp;Mehdi Ghasemi,&nbsp;Rakhee R Lalla,&nbsp;Kimiyoshi J Kobayashi","doi":"10.14740/jocmr4945","DOIUrl":"https://doi.org/10.14740/jocmr4945","url":null,"abstract":"<p><strong>Background: </strong>Telestroke is an established telemedicine method of delivering emergency stroke care. However, not all neurological patients utilizing telestroke service require emergency interventions or transfer to a comprehensive stroke center. To develop an understanding of the appropriateness of inter-hospital neurological transfers utilizing the telemedicine, our study aimed to assess the differences in outcomes of inter-hospital transfers utilizing the service in relation to the need for neurological interventions.</p><p><strong>Methods: </strong>The pragmatic, retrospective analysis included 181 consecutive patients, who were emergently transferred from telestroke-affiliated regional medical centers between October 3, 2021, and May 3, 2022. In this exploratory study investigating the outcomes of telestroke-referred patients, patients receiving interventions were compared to those that did not following transfer to our tertiary center. Neurological interventions included mechanical thrombectomy (MT) and/or tissue plasminogen activator (tPA), craniectomy, electroencephalography (EEG), or external ventricular drain (EVD). Transfer mortality rate, discharge functional status defined by modified Rankin scale (mRS), neurological status defined by National Institutes of Health Stroke Scale (NIHSS), 30-day unpreventable readmission rate, 90-day clinical major adverse cardiovascular events (MACE), and 90-day mRS, and NIHSS were studied. We used χ<sup>2</sup> or Fisher exact tests to evaluate the association between the intervention and categorical or dichotomous variables. Continuous or ordinal measures were compared using Wilcoxon rank-sum tests. All tests of statistical significance were considered to be significant at P < 0.05.</p><p><strong>Results: </strong>Among the 181 transferred patients, 114 (63%) received neuro-intervention and 67 (37%) did not. The death rate during the index admission was not statistically significant between the intervention and non-intervention groups (P = 0.196). The discharge NIHSS and mRS were worse in the intervention compared to the non-intervention (P < 0.05 each, respectively). The 90-day mortality and cardiovascular event rates were similar between intervention and non-intervention groups (P > 0.05 each, respectively). The 30-day readmission rates were also similar between the two groups (14% intervention vs. 13.4% non-intervention, P = 0.910). The 90-day mRS were not significantly different between intervention and non-intervention groups (median 3 (IQR: 1 - 6) vs. 2 (IQR: 0 - 6), P = 0.109). However, 90-day NIHSS was worse in the intervention compared to non-intervention group (median 2 (IQR: 0 - 11) vs. 0 (IQR: 0 - 3), P = 0.004).</p><p><strong>Conclusions: </strong>Telestroke is a valuable resource that expedites emergent neurological care via referral to a stroke center. However, not all transferred patients benefit from the transfer process. Future multicenter studies are warranted to s","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 6","pages":"292-299"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/c5/jocmr-15-292.PMC10332878.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10664913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Contribution of COVID-19 to Acute Respiratory Distress Syndrome-Related Mortality in the United States. COVID-19对美国急性呼吸窘迫综合征相关死亡率的贡献
Pub Date : 2023-05-01 DOI: 10.14740/jocmr4915
Lavi Oud, John Garza
Acute respiratory distress syndrome (ARDS) is the most common severe pulmonary complication of the coronavirus disease 2019 (COVID-19). Although considered earlier in the pandemic to represent a different clinical entity than nonCOVID-19 ARDS [1], it is nevertheless estimated that ARDS is present in 75% of intensive care unit (ICU) patients with COVID-19 and in 90% of ICU non-survivors [2]. Importantly, autopsy data show that ARDS, as evidenced by findings of diffuse alveolar damage, is present either in all [3] or in the majority of decedents with COVID-19 [4]. The toll of pre-pandemic ARDS-related deaths in the United States was estimated at nearly 10,000/year [5]. With over 375,000 COVID-19-related deaths in the USA during the first year of the pandemic [6], the epidemiology of ARDS was likely transformed substantially [7]. Accurate accounting of the ARDS-related mortality burden during the COVID-19 pandemic can inform future preventive and interventional efforts, as well as health resource allocation. However, the impact of COVID-19 on ARDS-related mortality at a national level has not been quantified. We used the National Center for Health Statistics (NCHS) Multiple Cause of Death data set, which is available through the Centers for Disease Control Wide-ranging Online Data for Epidemiological Research (CDC WONDER) website [8] to obtain mortality and population data. The mortality data in NCHS are based on information from all death certificates filed in the 50 states and the District of Columbia, and provides up to 20 causes of death in addition to an underlying cause of death. We have identified decedents with a diagnosis of ARDS during 2015 2019, and with a diagnosis of COVID-19, ARDS, or both in 2020, listed among any of the 20 causes of death irrespective of the underlying cause of death, which could be ARDS, COVID-19, or other conditions (e.g., cardiovascular disease, etc.). ARDS and COVID-19 were identified by International Classification of Diseases, Tenth Revision, Clinical Modification codes J80 and J071, respectively. Negative binomial regression with log-link and robust standard errors was used on the 2015 2019 data to forecast the number of ARDS-related deaths in 2020. We then compared the number of observed vs. expected ARDS-related deaths in 2020. In addition, we examined the proportion of a diagnosis of COVID-19 among all decedents with a diagnosis of ARDS and reporting of a diagnosis of ARDS among all decedents with a diagnosis of COVID-19. We then repeated the later analysis within each of the Department of Health and Human Services (HHS) Regions. Data analysis was performed using R 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria). The annual ARDS-related mortality and population data for 2015 2020 are detailed in Table 1. In 2020, there were 51,184 ARDS-related deaths, 384,536 COVID-19-related deaths, and 41,606 deaths with both in the USA. The predicted number of ARDS-related deaths for 2020 was 10,851 (95%
{"title":"The Contribution of COVID-19 to Acute Respiratory Distress Syndrome-Related Mortality in the United States.","authors":"Lavi Oud,&nbsp;John Garza","doi":"10.14740/jocmr4915","DOIUrl":"https://doi.org/10.14740/jocmr4915","url":null,"abstract":"Acute respiratory distress syndrome (ARDS) is the most common severe pulmonary complication of the coronavirus disease 2019 (COVID-19). Although considered earlier in the pandemic to represent a different clinical entity than nonCOVID-19 ARDS [1], it is nevertheless estimated that ARDS is present in 75% of intensive care unit (ICU) patients with COVID-19 and in 90% of ICU non-survivors [2]. Importantly, autopsy data show that ARDS, as evidenced by findings of diffuse alveolar damage, is present either in all [3] or in the majority of decedents with COVID-19 [4]. The toll of pre-pandemic ARDS-related deaths in the United States was estimated at nearly 10,000/year [5]. With over 375,000 COVID-19-related deaths in the USA during the first year of the pandemic [6], the epidemiology of ARDS was likely transformed substantially [7]. Accurate accounting of the ARDS-related mortality burden during the COVID-19 pandemic can inform future preventive and interventional efforts, as well as health resource allocation. However, the impact of COVID-19 on ARDS-related mortality at a national level has not been quantified. We used the National Center for Health Statistics (NCHS) Multiple Cause of Death data set, which is available through the Centers for Disease Control Wide-ranging Online Data for Epidemiological Research (CDC WONDER) website [8] to obtain mortality and population data. The mortality data in NCHS are based on information from all death certificates filed in the 50 states and the District of Columbia, and provides up to 20 causes of death in addition to an underlying cause of death. We have identified decedents with a diagnosis of ARDS during 2015 2019, and with a diagnosis of COVID-19, ARDS, or both in 2020, listed among any of the 20 causes of death irrespective of the underlying cause of death, which could be ARDS, COVID-19, or other conditions (e.g., cardiovascular disease, etc.). ARDS and COVID-19 were identified by International Classification of Diseases, Tenth Revision, Clinical Modification codes J80 and J071, respectively. Negative binomial regression with log-link and robust standard errors was used on the 2015 2019 data to forecast the number of ARDS-related deaths in 2020. We then compared the number of observed vs. expected ARDS-related deaths in 2020. In addition, we examined the proportion of a diagnosis of COVID-19 among all decedents with a diagnosis of ARDS and reporting of a diagnosis of ARDS among all decedents with a diagnosis of COVID-19. We then repeated the later analysis within each of the Department of Health and Human Services (HHS) Regions. Data analysis was performed using R 4.0.5 (R Foundation for Statistical Computing, Vienna, Austria). The annual ARDS-related mortality and population data for 2015 2020 are detailed in Table 1. In 2020, there were 51,184 ARDS-related deaths, 384,536 COVID-19-related deaths, and 41,606 deaths with both in the USA. The predicted number of ARDS-related deaths for 2020 was 10,851 (95% ","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"279-281"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/80/jocmr-15-279.PMC10251696.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Timing of Postoperative Stroke and Risk of Mortality After Noncardiac Surgery: A Cohort Study. 非心脏手术后卒中时间和死亡风险:一项队列研究。
Pub Date : 2023-05-01 DOI: 10.14740/jocmr4877
Christian Mpody, Onaopepo Kola-Kehinde, Hamdy Awad, Sujatha Bhandary, Michael Essandoh, Demicha Rankin, Antolin Flores, Ronald Harter, Olubukola O Nafiu

Background: Postoperative stroke is a devastating complication of surgery, given its association with severe long-term disability and mortality. Previous investigators have confirmed the association of stroke with postoperative mortality. However, limited data exist regarding the relationship between the timing of stroke and survival. Addressing this knowledge gap will help clinicians develop tailored perioperative strategies to reduce the incidence, severity, and mortality associated with perioperative stroke. Therefore, our objective was to determine whether the timing of postoperative stroke influenced mortality risk.

Methods: We performed a retrospective cohort study of patients > 18 years who underwent noncardiac surgery and developed postoperative stroke during the first 30 days of surgery (National Surgical Quality Improvement Program Pediatrics 2010 - 2021). Our primary outcome was 30-day mortality following the occurrence of postoperative stroke. We subdivided patients into two mutually exclusive groups: early and delayed stroke. Early stroke was defined as the occurrence within 7 days following surgery, consistent with a previous study.

Results: We identified 16,750 patients who underwent noncardiac surgery and developed stroke within 30 days of surgery. Of these, 11,173 (66.7%) had an early postoperative stroke (≤ 7 days). Perioperative physiological status, operative characteristics, and preoperative comorbidities were generally comparable between patients with early and delayed postoperative stroke. Despite the comparability in these clinical characteristics, the mortality risk was 24.9% for early and 19.4% for delayed stroke. After adjusting for perioperative physiological status, operative characteristics, and preoperative comorbidities, early stroke was associated with an increased mortality risk (adjusted odds ratio: 1.39, confidence interval: 1.29 - 1.52, P-value < 0.001). In patients with an early postoperative stroke, the most common preceding complications were bleeding requiring transfusion (24.3%), followed by pneumonia (13.2%) and renal insufficiency (11.3%).

Conclusions: Postoperative stroke tends to occur within 7 days following noncardiac surgery. Such timing of postoperative stroke carries a higher mortality risk, suggesting that targeted efforts to prevent stroke should focus on the first week following surgery to reduce the incidence and mortality associated with this complication. Our findings contribute to the growing understanding of stroke after noncardiac surgery and may help clinicians develop tailored perioperative neuroprotective strategies to prevent or improve treatment and outcomes of postoperative stroke.

背景:术后卒中是一种破坏性的手术并发症,它与严重的长期残疾和死亡率有关。先前的研究者已经证实了卒中与术后死亡率的关联。然而,关于中风时间与生存之间关系的数据有限。解决这一知识差距将有助于临床医生制定量身定制的围手术期策略,以降低围手术期卒中的发病率、严重程度和死亡率。因此,我们的目的是确定术后中风的时机是否影响死亡风险。方法:我们对> 18岁的非心脏手术患者进行了回顾性队列研究,这些患者在手术前30天发生了术后卒中(2010 - 2021年国家儿科手术质量改进计划)。我们的主要终点是术后卒中发生后的30天死亡率。我们将患者细分为两个相互排斥的组:早期卒中和延迟卒中。早期中风定义为手术后7天内发生,与先前的研究一致。结果:我们确定了16,750例接受非心脏手术并在手术30天内发生中风的患者。其中11,173例(66.7%)发生术后早期卒中(≤7天)。早期和术后延迟卒中患者的围手术期生理状态、手术特征和术前合并症一般具有可比性。尽管这些临床特征具有可比性,但早期卒中的死亡率为24.9%,迟发性卒中的死亡率为19.4%。在调整围手术期生理状态、手术特征和术前合并症后,早期卒中与死亡风险增加相关(校正优势比:1.39,置信区间:1.29 - 1.52,p值< 0.001)。术后早期卒中患者最常见的并发症是出血需要输血(24.3%),其次是肺炎(13.2%)和肾功能不全(11.3%)。结论:术后卒中多发生在非心脏手术后7天内。这样的术后中风时间有较高的死亡风险,提示有针对性的预防中风的努力应该集中在手术后的第一周,以减少与此并发症相关的发病率和死亡率。我们的研究结果有助于加深对非心脏手术后卒中的了解,并可能帮助临床医生制定量身定制的围手术期神经保护策略,以预防或改善术后卒中的治疗和预后。
{"title":"Timing of Postoperative Stroke and Risk of Mortality After Noncardiac Surgery: A Cohort Study.","authors":"Christian Mpody,&nbsp;Onaopepo Kola-Kehinde,&nbsp;Hamdy Awad,&nbsp;Sujatha Bhandary,&nbsp;Michael Essandoh,&nbsp;Demicha Rankin,&nbsp;Antolin Flores,&nbsp;Ronald Harter,&nbsp;Olubukola O Nafiu","doi":"10.14740/jocmr4877","DOIUrl":"https://doi.org/10.14740/jocmr4877","url":null,"abstract":"<p><strong>Background: </strong>Postoperative stroke is a devastating complication of surgery, given its association with severe long-term disability and mortality. Previous investigators have confirmed the association of stroke with postoperative mortality. However, limited data exist regarding the relationship between the timing of stroke and survival. Addressing this knowledge gap will help clinicians develop tailored perioperative strategies to reduce the incidence, severity, and mortality associated with perioperative stroke. Therefore, our objective was to determine whether the timing of postoperative stroke influenced mortality risk.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients > 18 years who underwent noncardiac surgery and developed postoperative stroke during the first 30 days of surgery (National Surgical Quality Improvement Program Pediatrics 2010 - 2021). Our primary outcome was 30-day mortality following the occurrence of postoperative stroke. We subdivided patients into two mutually exclusive groups: early and delayed stroke. Early stroke was defined as the occurrence within 7 days following surgery, consistent with a previous study.</p><p><strong>Results: </strong>We identified 16,750 patients who underwent noncardiac surgery and developed stroke within 30 days of surgery. Of these, 11,173 (66.7%) had an early postoperative stroke (≤ 7 days). Perioperative physiological status, operative characteristics, and preoperative comorbidities were generally comparable between patients with early and delayed postoperative stroke. Despite the comparability in these clinical characteristics, the mortality risk was 24.9% for early and 19.4% for delayed stroke. After adjusting for perioperative physiological status, operative characteristics, and preoperative comorbidities, early stroke was associated with an increased mortality risk (adjusted odds ratio: 1.39, confidence interval: 1.29 - 1.52, P-value < 0.001). In patients with an early postoperative stroke, the most common preceding complications were bleeding requiring transfusion (24.3%), followed by pneumonia (13.2%) and renal insufficiency (11.3%).</p><p><strong>Conclusions: </strong>Postoperative stroke tends to occur within 7 days following noncardiac surgery. Such timing of postoperative stroke carries a higher mortality risk, suggesting that targeted efforts to prevent stroke should focus on the first week following surgery to reduce the incidence and mortality associated with this complication. Our findings contribute to the growing understanding of stroke after noncardiac surgery and may help clinicians develop tailored perioperative neuroprotective strategies to prevent or improve treatment and outcomes of postoperative stroke.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"268-273"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/e5/jocmr-15-268.PMC10251695.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9673112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of Non-Tachycardic Atrial Fibrillation Whose Left Ventricular Systolic Dysfunction Improved After Catheter Ablation. 非心动过速性心房颤动经导管消融后左室收缩功能改善1例。
Pub Date : 2023-05-01 DOI: 10.14740/jocmr4908
Asami Yamashita, Shunsuke Kiuchi, Takanori Ikeda

It is difficult to identify the causes and optimal treatment of heart failure (HF) in patients with atrial fibrillation (AF) and HF with reduced ejection fraction (EF) (HFrEF). Tachyarrhythmia can cause left ventricular (LV) systolic dysfunction called tachycardia-induced cardiomyopathy (TIC). In patients with TIC, conversion to sinus rhythm may lead to improvement in LV systolic dysfunction. However, it is unclear whether we should try to convert patients with AF without tachycardia to sinus rhythm. A 46-year-old man with chronic AF and HFrEF came to our hospital. His New York Heart Association (NYHA) classification was class II. The blood test showed a brain natriuretic peptide of 105 pg/mL. Electrocardiogram (ECG) and 24-h ECG showed AF without tachycardia. Transthoracic echocardiography (TTE) showed left atrial (LA) dilatation, LV dilatation, and diffuse LV hypokinesis (EF was 40%). Although he was optimized medically, NYHA classification II persisted. Therefore, he underwent direct current cardioversion and catheter ablation. After his AF converted to a sinus rhythm of heart rate (HR) 60 - 70 beats per minute (bpm), TTE showed improvement in LV systolic dysfunction. We gradually reduced oral medications for arrhythmia and HF. We subsequently succeeded in discontinuing all medications 1 year after catheter ablation. TTE performed between 1 and 2 years after catheter ablation showed normal LV function and normal cardiac size. During the 3 years of follow-up, there was no recurrence of AF, and he was not readmitted to the hospital. This patient showed the effectiveness of converting AF to sinus rhythm in patients without tachycardia.

心房颤动(AF)和HF伴射血分数降低(HFrEF)患者心力衰竭(HF)的病因和最佳治疗方法难以确定。心动过速可引起左心室收缩功能障碍,称为心动过速性心肌病(TIC)。在TIC患者中,转换为窦性心律可能导致左室收缩功能障碍的改善。然而,尚不清楚我们是否应该尝试将无心动过速的房颤患者转化为窦性心律。一位46岁男性慢性房颤合并HFrEF来我院就诊。他的纽约心脏协会(NYHA)分级为II级。血液检查显示脑利钠肽105pg /mL。心电图及24小时心电图示房颤,无心动过速。经胸超声心动图(TTE)显示左房(LA)扩张,左室扩张,弥漫性左室低运动(EF为40%)。虽然他在医学上得到了优化,但NYHA II级仍然存在。因此,他接受了直流电复律和导管消融。在他的房颤转换为心率(HR) 60 - 70次/分钟(bpm)后,TTE显示左室收缩功能障碍改善。我们逐渐减少了心律失常和心衰的口服药物治疗。我们在导管消融后1年成功停用所有药物。在导管消融后1 - 2年间进行TTE,显示左室功能正常,心脏大小正常。随访3年,无房颤复发,无再次住院。该患者在无心动过速的患者中显示了将房颤转化为窦性心律的有效性。
{"title":"A Case of Non-Tachycardic Atrial Fibrillation Whose Left Ventricular Systolic Dysfunction Improved After Catheter Ablation.","authors":"Asami Yamashita,&nbsp;Shunsuke Kiuchi,&nbsp;Takanori Ikeda","doi":"10.14740/jocmr4908","DOIUrl":"https://doi.org/10.14740/jocmr4908","url":null,"abstract":"<p><p>It is difficult to identify the causes and optimal treatment of heart failure (HF) in patients with atrial fibrillation (AF) and HF with reduced ejection fraction (EF) (HFrEF). Tachyarrhythmia can cause left ventricular (LV) systolic dysfunction called tachycardia-induced cardiomyopathy (TIC). In patients with TIC, conversion to sinus rhythm may lead to improvement in LV systolic dysfunction. However, it is unclear whether we should try to convert patients with AF without tachycardia to sinus rhythm. A 46-year-old man with chronic AF and HFrEF came to our hospital. His New York Heart Association (NYHA) classification was class II. The blood test showed a brain natriuretic peptide of 105 pg/mL. Electrocardiogram (ECG) and 24-h ECG showed AF without tachycardia. Transthoracic echocardiography (TTE) showed left atrial (LA) dilatation, LV dilatation, and diffuse LV hypokinesis (EF was 40%). Although he was optimized medically, NYHA classification II persisted. Therefore, he underwent direct current cardioversion and catheter ablation. After his AF converted to a sinus rhythm of heart rate (HR) 60 - 70 beats per minute (bpm), TTE showed improvement in LV systolic dysfunction. We gradually reduced oral medications for arrhythmia and HF. We subsequently succeeded in discontinuing all medications 1 year after catheter ablation. TTE performed between 1 and 2 years after catheter ablation showed normal LV function and normal cardiac size. During the 3 years of follow-up, there was no recurrence of AF, and he was not readmitted to the hospital. This patient showed the effectiveness of converting AF to sinus rhythm in patients without tachycardia.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 5","pages":"274-278"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/4d/jocmr-15-274.PMC10251699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Medicine Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1